Breaking Now: 60 Degrees Pharma (Nasdaq: SXTP)'s Babesiosis Trial Gets Boston Boost

*Sponsored by 60 Degrees Pharmaceuticals, Inc. Just Announced! 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) Is Our Next Potential Breakout Idea! And Here’s Why… Ultra-Low Float: Only 1.5M shares in the float, sets the stage for significant swing potential if demand begins to shift. Insider Confidence: CEO insider purchases highlight strong belief in the company’s future and growth prospects. Analyst Target: A $3.40 target suggests 119% upside potential from yesterday’s $1.55 open (on 12/10). Momentum Potential: An approximate 182% move over the past six weeks signals growing public interest. Strong Intellectual Property: Over 40 patents, including three Orange Book-listed patents, provide market exclusivity and innovation strength. FDA-Approved Product: ARAKODA®, addressing a $50–$70M U.S. malaria market, is FDA-approved and commercially available. Expanding Pipeline: Pivotal trials for tick-borne diseases and chronic illnesses position the company in key emerging markets. Consider adding 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) to your watchlist this week… December 11, 2024 Dear Reader, Boom!  60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) just raised the stakes in the fight against severe babesiosis.  The company has teamed up with none other than Brigham and Women’s Hospital to expand its tafenoquine clinical trial.  With tick-borne illnesses on the rise, this double-blind, placebo-controlled trial is addressing a critical unmet medical need for hospitalized patients suffering from this life-threatening condition. Led by esteemed researchers Dr. Ann Woolley and Dr. David Leaf, the study will evaluate tafenoquine alongside standard treatments, aiming to improve recovery times and deliver molecular cures.  Babesiosis often flies under the radar but can be a serious co-infection of Lyme disease, particularly dangerous for the elderly and immunosuppressed. This move helps to position (SXTP) as a trailblazer in tackling an infectious disease steadily gaining ground across the U.S. Northeast.  With interim results slated for 2026 and a potentially massive market opportunity of over 400,000 patients through 2035, the stakes couldn’t be higher.  CEO Geoffrey Dow expressed confidence in the collaboration’s potential to transform babesiosis treatment, cementing 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s innovative legacy. Tafenoquine, already a U.S.-approved malaria prophylaxis under the brand name ARAKODA®, is showing promise for babesiosis in early studies. While not yet FDA-approved for this indication, the signs are undeniably exciting.  If you missed my previous email on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP), keep reading to get up to speed. This biotech profile has several potential catalysts you want to see like: An ultra-low float of only 1.5M shares, setting the stage for potential swings.  The CEO purchased over 70,000 shares in the last week, potentially signaling strong confidence. Analyst target suggests 119% potential upside target. An approximate 182% move in six weeks, could suggest the public is starting to catch on. Strong intellectual property portfolio with over 40 patents Triggering 16 Bullish Signals on TradingView’s technical analysis tool Let’s dive into why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is #1 on our watchlist this morning.  In the high-stakes world of pharmaceutical innovation, few companies dare to challenge the norms with as much confidence and expertise as 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP).  Focused on addressing critical unmet needs in infectious disease treatment, 60P has built a robust portfolio that combines scientific ingenuity with a relentless drive for results.  From malaria prevention to tackling tick-borne illnesses like babesiosis, this company is setting the gold standard for innovation, commercial growth, and global impact. A Game-Changer in Malaria Prevention ARAKODA® (tafenoquine), 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s flagship product, is a revolutionary antimalarial therapy that earned FDA approval in 2018 and became commercially available the following year.  Unlike other treatments, ARAKODA® provides complete protection against all stages of malaria with a convenient weekly dosing schedule—no resistance, no hassle.  Its unique attributes, including broad-spectrum activity, have earned recommendations from the CDC and cemented its reputation as the top choice for malaria prophylaxis. With a $50–$70 Mln U.S. market for malaria prevention alone, ARAKODA® has already established a foothold in a critical space, showing consistent sales growth.  And let’s not overlook the bigger picture: a global burden of 249 Mln malaria cases annually underscores the dire need for solutions like ARAKODA®. Expanding Horizons: Tackling Tick-Borne Diseases Not content with its success in malaria, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is charging ahead in the treatment of babesiosis, a tick-borne disease on the rise in the U.S.  The company has launched pivotal trials for acute babesiosis and plans to address chronic cases next.  FDA orphan status for tafenoquine highlights its potential as the only game in town for a disease where existing treatments lack efficacy. Babesiosis isn’t just a public health issue—it’s a market with significant potential. With up to 1 Mln chronic cases in the U.S. and growing acute incidence rates, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is positioning itself to dominate this emerging space, potentially expanding its patient reach to over 2 Mln. Strong Intellectual Property Portfolio A critical driver of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s success is its robust and expanding intellectual property portfolio.  The company holds three Orange Book-listed patents for tafenoquine, protecting its malaria prevention innovations until 2035.  With 42 additional patents filed, pending, or optioned across multiple therapeutic areas—including tick-borne diseases and respiratory viruses—60P is playing a long game, ensuring market exclusivity and driving future growth. A Leadership Team That Delivers Behind this powerhouse is a leadership team with unmatched experience and credentials. CEO Geoffrey Dow is a 20-year veteran in tropical disease product development, having spearheaded the regulatory approval of ARAKODA®.  Chief Medical Officer Bryan Smith, with 30+ years of clinical expertise, brings unparalleled insight into pharmacovigilance and regulatory strategy.  And let’s not forget Chief Commercial Officer Kristen Landon, who has launched more than a dozen blockbuster brands, driving revenues well into nine figures. This team isn’t just talking the talk—they’re walking the walk, executing on ambitious plans to scale commercial operations and meet aggressive pro-fit-ability targets by Q4 2026. Evolving Strategies for Commercial Growth 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s commercial strategy for ARAKODA® is razor-sharp: differentiate it from generic competitors with a compelling value story, expand its use among healthcare providers, and reduce access barriers through co-pay assistance programs.  This targeted approach has already shown results, with organic sales growth reflecting increased awareness among prescribers in the Lyme disease community. And it doesn’t stop there.  The company’s forward-looking pipeline includes Celgosivir, targeting dengue and respiratory viruses, and an exploratory program for canine babesiosis, hinting at diversification into veterinary markets. Fiscal Momentum and Milestones Ahead The numbers don’t lie. Recent rounds have injected over $5.9M into 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s coffers, enabling critical funding in commercialization and clinical development.  With three babesiosis trials underway, the company is poised to deliver interim results by early 2026—just in time to accelerate its push toward pro-fit-ability. Upcoming potential catalysts include sales growth milestones, new product development collaborations, and regulatory submissions.  If history is any guide, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) isn’t just checking boxes; it’s carving out its place in the biotech space. The Bottom Line 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is more than a pharma company—it’s a force to be reckoned with in the fight against infectious diseases.  With groundbreaking products, a visionary leadership team, and an aggressive roadmap for growth, (SXTP) is redefining what’s possible in this space.  For those watching closely, one thing is clear: this company doesn’t just participate—it dominates. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is drawing attention with several potential catalysts that could help drive its momentum.  With a razor-thin float of only 1.5M shares, the company is positioned for potential market movements.  Recent insider purchases by the CEO reflect confidence in its direction, while a 119% upside target points to notable growth potential. The company has also seen approximately 182% movement over the past six weeks, an indicator of growing market interest.  As of yesterday (12/10), (SXTP) was triggering 16 Bullish Signals on TradingView’s technical analysis tool using the 30 minute time-frames.  Coupled with a robust intellectual property portfolio of over 40 patents, the company is positioning itself to advance its efforts in addressing unmet medical needs.  These elements create a compelling case for keeping an eye on this emerging biotech player. 7 Reasons Why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)  is #1 On Our Watchlist This Morning… 1. Razor-Thin Float: With just 1.5M shares in the float, the stage is set for the potential of big swings if demand begins to change.  2. Insider Confidence: The CEO purchased over 70,000 shares over the last week which could signal strong belief in the company’s future, showcasing leadership's commitment to growth. 3. Analyst Target Highlights Growth Potential: Analyst’s $3.40 target suggests a 119% upside potential from yesterday’s $1.18 open on 12/10. 4. Building Momentum: An approximate 182% move over the past six weeks could suggest the public is starting to catch on to  5. Strong Intellectual Property: Boasting over 40 patents, including three Orange Book-listed patents for its flagship malaria treatment, the company has built a solid foundation for innovation and market exclusivity. 6. FDA-Approved Product: The company’s flagship product, ARAKODA®, is already FDA-approved and commercially available, addressing a $50–$70M U.S. malaria prevention market while targeting a global health crisis. 7. Expanding Pipeline: The company’s ongoing pivotal trials for tick-borne disease treatments and plans for addressing chronic illnesses position it as a key player in emerging medical markets. Consider Adding 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) to Your Radar This Week… 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has all the hallmarks of a biotech worth paying attention to. With an ultra-low float of just 1.5M shares, the potential for significant market movement is clear.  Insider confidence is evident with recent CEO purchases, while Lucas Ward, an analyst at Ascendiant Capital Markets, recently set a $3.40 target on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) which suggests 119% upside potential underscores the growth potential from yesterday’s opening level of around $1.18. The company’s potential momentum appears to be already building, with an approximate 182% move in the past six weeks, (from $.7012 on 10/30 to $1.98 on 12/10), signaling growing public interest. Its robust intellectual property portfolio of over 40 patents, combined with the FDA-approved ARAKODA®, places it in a strong position to capitalize on the $50–$70M U.S. malaria prevention market and address critical global health challenges. Looking ahead, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is not just relying on its success in malaria; its expanding pipeline targeting tick-borne diseases and chronic illnesses demonstrates its commitment to innovation and long-term growth.  This is a company with the vision, leadership, and foundation to make a meaningful impact in the biotech sector. Remember, (SXTP) only has 1.5M shares listed in the public float, with a recent analyst target suggesting 119% in potential upside.  Consider starting your research on (SXTP) tonight and have it on your screen before the opening bell rings tomorrow. As of yesterday (12/10), (SXTP) was triggering 16 Bullish Signals on the 30 minute time-frame. Quick reminder, there’s only around 1.5M shares in the float, and the CEO just acquired over 70,000 shares this past week. And 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) just raised the stakes in the fight against severe babesiosis by teaming up with none other than Brigham and Women’s Hospital to expand its tafenoquine clinical trial. We’ll be covering (SXTP) early this morning so keep a lookout for my updates. I’ll check back in with you shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and 60 Degrees Pharmaceuticals Inc., TD Media LLC has been hired for a period beginning on 12/9/2024 and ending on 12/11/2024 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, we have been paid ninety-nine thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US). Neither TD Media LLC or its member owns shares of (SXTP:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/sxtp/

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice